Prana Biosciences
↗Worcester, USA
Prana Biosciences is an early-stage hybrid biotechnology and biomanufacturing company focused on developing 'biobetters'—improved versions of existing, successful therapeutics. The company leverages a proprietary platform that combines advanced antibody design with AI-supported enhancements to improve the binding, function, and delivery of monoclonal antibodies (mAbs) and small molecules.
The company primarily utilizes the 505(b)(2) regulatory pathway to accelerate the development of value-enhanced pharmaceutical products. Their current focus areas include oncology, immunology, and pain management, with a mission to make high-cost biologic treatments more accessible and effective for a broader patient population.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Seed/Early Stage VC
Total Raised:$7.95M
Investors:Massachusetts Biomedical Initiatives (MBI), Private Angel Investors
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical / IND-enabling
Modalities:Monoclonal antibodies (mAbs), Small molecule, Biobetters, Oral formulations
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Massachusetts Biomedical Initiatives (Incubator partner)
COMPETITION
Position:Emerging
Competitors:Alkermes, Indivior, Halozyme Therapeutics, Xencor, Amgen (Biosimilars division)
LEADERSHIP
Key Executives:
Prabu Nambiar - Founder & CEO
Bharat Tewarie - CEO (Recent Appointment/Co-Lead)
Scientific Founders:Prabu Nambiar, Binesh Prabhakar, Geevarghese Easo
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Prana Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Prana Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.